Lakewood-Amedex Biotherapeutics Inc Dossier - Source-backed chat

Lakewood-Amedex Biotherapeutics Inc

LABTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.93Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.2M

Shares Outstanding 2.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials known as Bisphosphocins. The company's lead candidate, Nu-3, is a topical gel formulation targeting infected diabetic foot ulcers (iDFU), a high-unmet-need indication with a massive addressable market. Following its direct listing on Nasdaq in April 2026, the stock has experienced extreme volatility and a sharp decline, presenting a highly speculative but potentially rewarding entry point for investors. The investment thesis is anchored on the unique physical membrane-disrupting mechanism of action of the Bisphosphocin platform, which has demonstrated a high barrier to resistance in preclinical testing, and the upcoming initiation of its Phase 2a clinical trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$12.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0020%

Nu-3 Gel fails to demonstrate sufficient safety or antimicrobial efficacy in the Phase 2a trial, or encounters severe enrollment delays. The company is unable to secure additional financing as its cash reserves from the April 2026 Series C placement are exhausted, leading to severe dilution, a potential delisting from Nasdaq, or insolvency.

Base CaseCentral scenario

$12.0055%

Matches the consensus mean

The company successfully initiates and completes the Phase 2a trial for Nu-3 Gel under the guidance of its CRO partner, PERI. Preclinical safety and resistance data are replicated in early human cohorts, establishing proof of concept. However, the company remains capital-constrained, requiring further dilutive equity raises or convertible debt to fund the larger Phase 2b trial, which caps near-term valuation upside.

Bull CaseUpside scenario

$12.0025%

Nu-3 Gel successfully completes its Phase 2a trial with strong safety and dose-response data, followed by rapid enrollment and positive efficacy signals in Phase 2b. The unique mechanism of action is validated as a breakthrough in combating antimicrobial resistance (AMR), attracting a major pharmaceutical partnership or acquisition. The company secures non-dilutive funding through government grants or the PASTEUR Act, mitigating its severe liquidity risks.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Novel physical mechanism of action that disrupts bacterial membranes, demonstrating a high barrier to resistance against multi-drug resistant strains (e.g., MRSA, VRE).
Targeting infected diabetic foot ulcers (iDFU), a major complication of diabetes with high morbidity and limited effective topical treatment options.
Strong intellectual property portfolio with 72 granted patents and 29 pending patents globally protecting the Bisphosphocin platform.
Led by an experienced management team with deep pharmaceutical development backgrounds, including CEO Kelvin Cooper (former Pfizer SVP).

Key Investment Risks

Extremely precarious financial position with only $11,709 in cash as of March 31, 2026, relying heavily on the net proceeds of the $7.5 million Series C Preferred Stock private placement closed in April 2026.
High concentration of pipeline risk, with the company's near-term prospects almost entirely dependent on the clinical success of a single asset, Nu-3.
Extreme stock price volatility and selling pressure following its April 2026 direct listing and subsequent 1-for-10 reverse stock split in June 2026.

Thesis Invalidation Triggers

Failure of Nu-3 Gel to meet safety or tolerability endpoints in the upcoming Phase 2a clinical trial.
Inability to secure additional funding or strategic partnerships before the exhaustion of Series C capital.
Regulatory delays or clinical holds imposed by the FDA on the Investigational New Drug (IND) application or trial protocols.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.